PriceTargets.com logo

Kamada - KMDA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 107.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.30 As of 09/28/2023 01:16 PM ET
▲ +0.21 (4.13%)

This chart shows the closing price for KMDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kamada Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KMDA

Analyst Price Target is $11.00
▲ +107.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kamada in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 107.55% upside from the last price of $5.30.

This chart shows the closing price for KMDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Kamada. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
3/16/2023HC WainwrightReiterated RatingBuy$11.00Low
11/23/2021HC WainwrightReiterated RatingBuyLow
8/14/2020Chardan CapitalBoost TargetPositive ➝ Buy$7.00 ➝ $11.00High
8/13/2020HC WainwrightReiterated RatingBuy$11.00Low
5/19/2020HC WainwrightReiterated RatingBuy$11.00High
12/23/2019HC WainwrightReiterated RatingBuy$11.00Medium
8/7/2019HC WainwrightReiterated RatingBuy$11.00Low
5/17/2019Chardan CapitalReiterated RatingBuy$7.00Low
2/14/2019HC WainwrightReiterated RatingBuy$11.00Low
(Data available from 9/28/2018 forward)

News Sentiment Rating

1.84 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Kamada logo
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $5.30
Low: $5.17
High: $5.34

50 Day Range

MA: $5.28
Low: $4.86
High: $5.83

52 Week Range

Now: $5.30
Low: $3.72
High: $5.85

Volume

10,942 shs

Average Volume

32,106 shs

Market Capitalization

$237.55 million

P/E Ratio

66.26

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Kamada?

The following Wall Street analysts have issued stock ratings on Kamada in the last twelve months: HC Wainwright, StockNews.com, and TheStreet.
View the latest analyst ratings for KMDA.

What is the current price target for Kamada?

1 Wall Street analysts have set twelve-month price targets for Kamada in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 107.5%. HC Wainwright has the highest price target set, predicting KMDA will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Kamada in the next year.
View the latest price targets for KMDA.

What is the current consensus analyst rating for Kamada?

Kamada currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KMDA will outperform the market and that investors should add to their positions of Kamada.
View the latest ratings for KMDA.

What other companies compete with Kamada?

Other companies that are similar to Kamada include Verastem, Immuneering, Inventiva, Renovaro Biosciences and Akebia Therapeutics. Learn More about companies similar to Kamada.

How do I contact Kamada's investor relations team?

Kamada's physical mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company's listed phone number is (728) 940-6472 and its investor relations email address is [email protected]. The official website for Kamada is www.kamada.com. Learn More about contacing Kamada investor relations.